Compassionate useMitochondrial Peptide
Compound 61613
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061613
Risk Class
MODERATE
Last Audit
May 6, 2108
Research Abstract
Mitochondrial Peptide candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61613 is a mitochondrial peptide asset inside mitochondrial peptide innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in compassionate use with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061613 with updates logged 2108-05-06.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61613Mitochondrial Peptide Program 61613
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061613
- [2] Operations Pulse • Mitochondrial Peptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61613